Shanthi Rexaline

Shanthi is a contributor to InvestorPlace.com and works as a Staff Writer with Benzinga. Equipped with a Bachelor’s degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors.

Recent Articles

EVgo Stock Needs to Boost Its Growth to Really Accelerate

By Shanthi Rexaline

EVgo stock could get moving if the company can capitalize on the vast opportunity provided by it many partnerships.

7 Potential Biotech Stocks Buyout Targets in 2022

By Shanthi Rexaline

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products.

4 Undervalued Biotech Stocks to Add to Your Buy List

By Shanthi Rexaline

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

3 Reasons Why Once High-flying EV Stock Rivian Remains Grounded

By Shanthi Rexaline

RIVN stock is overvalued even with the steep drop from its post-IPO highs. Redemption isn't at sight at least in the near term.

Hold on to the Steering Wheel, KMX Stock Investors! CarMax Just Had a Clunker of a Q1

By Shanthi Rexaline

CarMax's fourth quarter came as a disappointment, with earnings trailing estimates. Don't jump into KMX stock for now.

Load More